SPECTRUM OF DISEASE, MANAGEMENT, EFFICIENCY, CLINICAL PROFILE AND OUTCOMES OF RETROVIRAL DISEASE PATIENTS
-
Published:2021-12-04
Issue:09
Volume:58
Page:47-51
-
ISSN:0019-462X
-
Container-title:INDIAN DRUGS
-
language:en
-
Short-container-title:IND. DRU.
Author:
Talasila Narmada,Papatla Amith S.,Thummanapally Ragini,Bakshi Vasudha,Kumar B Hemanth,Kumar G Rajeev,Kumar K Vivek,
Abstract
HIV is a virus that targets and alters the immune system, increasing the risk and impact of other infections and diseases. Without treatment, the infection might progress to an advanced disease stage called AIDS. A prospective study was conducted for a period of 6 months in a tertiary care hospital with the sample size of 102 patients. A data collection form was taken, which includes the details of demographics date of visit to the hospital, diagnosis, past and current medication history. 102 Inpatients and Outpatients diagnosed with HIV were considered. For the management of HIV, 52 % of 2 NRTI and 1 NNRTI combination and 35 % of 2 NRTI and 1 integrase inhibitor combination were used. The drug usage pattern was found to be tenofovir 74.5 %, lamivudine 83.3 % and Efavirenz 50.9 %. The percentage of subjects with opportunistic infections was 66.6 % and, among these opportunistic infections, tuberculosis was found to be 47.05 %. The viral load after 6 months of ART was found to be undetectable in 95.09 % patients. The levels of CD4 counts were raised after initiation of the ART in 6 months of duration. The death rate was found to be 4.90 %. Due to highly active antiretroviral therapy and effi cient opportunistic infection management, the patients had elevated CD4 levels and undetectable viral load. Hence HAART is highly effi cient in management of HIV which ultimately improves the quality of life of patients.
Publisher
Indian Drug Manufacturers' Association (IDMA)
Subject
Drug Discovery,Pharmaceutical Science,Pharmacology
Reference15 articles.
1. 1. Anonymous author, HIV Country Profile, Available at https://cfs.hivci.org/country-factsheet.html .Access Date - 10 February 2020. 2. 2. Masur H.: Recurring and emerging questions related to management of HIV-related opportunistic infections , Top Antivir Med., 2018, 26(3),79-84. 3. 3. Crump J. A., Ramadhani H. O., Morrissey A. B., Msuya L. J., Yang L. Y., Chow S. C., Morpeth S. C., Reyburn H., Njau B. N., Shaw A. V., Diefenthal H. C., Bartlett J. A., Shao J. F., Schimana W., Cunningham C. K. and Kinabo G. D.: Invasive bacterial and fungal infections among hospitalized HIV-infected and HIV-uninfected children and infants in northern Tanzania, Trop. Med. Int. Health, 2011, 16(7), 830–837. 4. 4. Gabillard D., Lewden C., Ndoye I., Moh R., Segeral O., Tonwe-Gold B., Etard J. F., Pagnaroat M., Fournier-Nicolle I., Eholié S., Konate I., Minga A., Mpoudi-Ngole E., Koulla-Shiro S., Zannou D. M., Anglaret X. and Laurent C.: Mortality, AIDS-morbidity, and loss to follow-up by current CD4 cell count among HIV-1-infected adults receiving antiretroviral therapy in Africa and Asia, J. Acquir. Immune Defic. Syndr., 1999, 62(5), 555–561. 5. 5. Phillips R.O., Steinmetz A., Nichols J., Adomako E., Ofori E., Antonio E., Allihien S.M., Peprah-Addae C. and Adams W.: Spectrum of disease in HIV-positive patients presenting to a tertiary care hospital: A retrospective, cross-sectional review in Kumasi, Ghana , BMC Infec. Dis., 2018, 18, 419, 1-7.
|
|